CN119679935A - Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 - Google Patents
Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 Download PDFInfo
- Publication number
- CN119679935A CN119679935A CN202411436609.3A CN202411436609A CN119679935A CN 119679935 A CN119679935 A CN 119679935A CN 202411436609 A CN202411436609 A CN 202411436609A CN 119679935 A CN119679935 A CN 119679935A
- Authority
- CN
- China
- Prior art keywords
- bcma
- cell
- cells
- gamma
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194470P | 2021-05-28 | 2021-05-28 | |
| US63/194470 | 2021-05-28 | ||
| US202163209694P | 2021-06-11 | 2021-06-11 | |
| US63/209694 | 2021-06-11 | ||
| CN202280038598.6A CN118043070A (zh) | 2021-05-28 | 2022-05-26 | Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 |
| PCT/EP2022/064362 WO2022248642A1 (en) | 2021-05-28 | 2022-05-26 | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280038598.6A Division CN118043070A (zh) | 2021-05-28 | 2022-05-26 | Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119679935A true CN119679935A (zh) | 2025-03-25 |
Family
ID=82115891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411436609.3A Pending CN119679935A (zh) | 2021-05-28 | 2022-05-26 | Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411525A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347039A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240014482A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119679935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022281104A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024822A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221399A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014139A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022248642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
-
2022
- 2022-05-26 KR KR1020237044376A patent/KR20240014482A/ko active Pending
- 2022-05-26 US US17/825,123 patent/US20220411525A1/en not_active Abandoned
- 2022-05-26 BR BR112023024822A patent/BR112023024822A2/pt not_active Application Discontinuation
- 2022-05-26 CA CA3221399A patent/CA3221399A1/en active Pending
- 2022-05-26 WO PCT/EP2022/064362 patent/WO2022248642A1/en not_active Ceased
- 2022-05-26 EP EP22731534.8A patent/EP4347039A1/en active Pending
- 2022-05-26 AU AU2022281104A patent/AU2022281104A1/en not_active Abandoned
- 2022-05-26 MX MX2023014139A patent/MX2023014139A/es unknown
- 2022-05-26 JP JP2023573168A patent/JP2024519545A/ja active Pending
- 2022-05-26 CN CN202411436609.3A patent/CN119679935A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023024822A2 (pt) | 2024-02-20 |
| WO2022248642A1 (en) | 2022-12-01 |
| US20220411525A1 (en) | 2022-12-29 |
| CA3221399A1 (en) | 2022-12-01 |
| EP4347039A1 (en) | 2024-04-10 |
| KR20240014482A (ko) | 2024-02-01 |
| MX2023014139A (es) | 2023-12-13 |
| JP2024519545A (ja) | 2024-05-15 |
| AU2022281104A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102928003B1 (ko) | Siglec-15를 위한 항체 및 이의 사용 방법 | |
| US10604580B2 (en) | Combination therapies with anti-CD38 antibodies | |
| AU2017257505B2 (en) | Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies | |
| CN116249548A (zh) | 用于治疗多发性骨髓瘤的方法 | |
| US20240209061A1 (en) | Fusion proteins and uses thereof | |
| US12110337B2 (en) | Anti-CD27 antibodies and uses thereof | |
| JP2016534090A (ja) | Cd38アゴニストの医学的使用 | |
| WO2020185739A1 (en) | Anti-icos antibodies for the treatment of cancer | |
| CA3232806A1 (en) | B7-h4 antibody-drug conjugates for the treatment of cancer | |
| WO2022058445A1 (en) | Methods for treating multiple myeloma | |
| US20220411525A1 (en) | Bcma as a target for t cell redirecting antibodies in b cell lymphomas | |
| CA3253669A1 (en) | Anti-CD39 antibodies and their use | |
| JP2024097985A (ja) | 抗gitr抗体およびその使用 | |
| KR20240099362A (ko) | 혈액암에 대한 lag-3 길항제 요법 | |
| EP4011918A1 (en) | Dual-specific protein | |
| CN118043070A (zh) | Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 | |
| TW202328206A (zh) | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 | |
| CN117957253A (zh) | 癌症的组合治疗中针对cd40和cd137的多特异性结合剂 | |
| HK40110611A (en) | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer | |
| EA047743B1 (ru) | Антитела к gitr и варианты их применения | |
| CA3124168A1 (en) | Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |